REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Biomarker Analysis ◽

Reverse Sequence ◽

Previously Treated ◽

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdy526 ◽

2019 ◽

Vol 30 (2) ◽

pp. 259-265 ◽

Cited By ~ 12

Author(s):

K. Shitara ◽

T. Yamanaka ◽

T. Denda ◽

Y. Tsuji ◽

K. Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated ◽

Rationale and study design of the PARERE trial: Randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2021.07.001 ◽

2021 ◽

Author(s):

Roberto Moretto ◽

Daniele Rossini ◽

Iolanda Capone ◽

Alessandra Boccaccino ◽

Federica Perrone ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Study Design ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

Annals of Oncology ◽

10.1093/annonc/mdy150.009 ◽

2018 ◽

Vol 29 ◽

pp. v95

Author(s):

T. Yoshino ◽

T. Yamanaka ◽

T. Denda ◽

Y. Tsuji ◽

K. Shinozaki ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated ◽

Life Analysis ◽

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/s12885-018-4001-x ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Marta Schirripa ◽

Federica Buggin ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

Annals of Oncology ◽

10.1093/annonc/mdy281.159 ◽

2018 ◽

Vol 29 ◽

pp. viii204

Author(s):

T. Mazard ◽

F. Ghiringhelli ◽

C. Mollevi ◽

E. Assenat ◽

C. Gavoille ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Dna Analysis ◽

Phase Ii Study ◽

Circulating Dna ◽

Wild Type ◽

Randomized Phase Ii ◽

Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01414-0 ◽

2019 ◽

Vol 24 (7) ◽

pp. 836-841

Author(s):

Hiroaki Tanioka ◽

Michitaka Honda ◽

Chihiro Tanaka ◽

Yoshitaka Morita ◽

Keiichiro Ishibashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Previously Treated ◽

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdf183 ◽

2002 ◽

Vol 13 (7) ◽

pp. 1072-1079 ◽

Cited By ~ 30

Author(s):

J.-F. Seitz ◽

J. Bennouna ◽

B. Paillot ◽

E. Gamelin ◽

E. François ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Phase II Study of Pulse 5-Fluoro-2′-Deoxyuridine and Leucovorin in Advanced Colorectal Cancer Patients Previously Treated with Chemotherapy

American Journal of Clinical Oncology ◽

10.1097/00000421-199204000-00004 ◽

1992 ◽

Vol 15 (2) ◽

pp. 115-118 ◽

Cited By ~ 1

Author(s):

John C. Marsh ◽

Henry J. Durivage ◽

Carol Davis ◽

Kyle OʼHollaren ◽

Dominick N. Pasquale ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

Previously Treated ◽

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Annals of Oncology ◽

10.1093/annonc/mdz082 ◽

2019 ◽

Vol 30 (5) ◽

pp. 796-803 ◽

Cited By ~ 5

Author(s):

C. Santos ◽

D. Azuara ◽

J.M. Viéitez ◽

D. Páez ◽

E. Falcó ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

High Sensitivity ◽